Table 1.

COVID‐19 therapeutics and potential challenges in patients with TCT ¹⁹

Therapeutic agent	Indication	Used in patients requiring oxygen	Use in ventilated patients	Potential CYP 450 interaction	Relevant adverse effects
Tixagevimab/cilgavimab	Sars‐CoV‐2 prophylaxis	No	No	No
Casirivimab plus imdevimab: anti‐spike protein monoclonal antibodies	Non‐Omicron infection	Yes	No		Pruritis, urticaria, erythema, dizziness lymphadenopathy post subcutaneous injection
	Mild disease
Remdesivir: RNA polymerase inhibitor	Mild‐moderate disease	Yes	No	Yes	Rash, headache transamimtis
	Within 7 days of symptom onset
Molnupiravir: ribonucleoside analogue	Mild disease	No	No		Dizziness
	Within 5 days of symptoms onset
Nirmatrelvir with ritonavir: protease inhibitors	Mild‐moderate disease	No	No	Yes Contraindicated with calcineurin inhibitor use
	Unvaccinated
	Within 5 days of symptoms onset
Sarilumab: IL‐6 inhibitor	Moderate to severe disease	Yes	Yes		Neutropenia, leukopenia
Tocilizumab: IL‐b inhibitor	Moderate to severe disease	Yes	Yes
	Evidence of systemic inflammation
Dexamethasone	Severe disease	Yes	Yes	Yes
Baricitinib: JAK1 inhibitor	Moderate to severe disease			Yes	Rare cytopenias

COVID‐19, coronavirus disease 2019; CYP450, cytochrome P450; IL, interleukin; TCT, chimeric antigen receptor T‐cell therapy.